EVGEN PHARMA PLC LS-0025
Research EVGEN PHARMA PLC LS-0025 (8EV) on Bullrun: market cap EUR 5.29M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker8EV
- ExchangeF
- CountryUnited Kingdom
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 5.29M
- Financial periodFY2025
- Revenue growth-100.0%
- Net income-EUR 1.94M
- Free cash flow-EUR 2.37M
Valuation Snapshot
latest market cap is EUR 5.29M.
About EVGEN PHARMA PLC LS-0025
Theracryf Plc, a clinical stage therapeutics company, engages in the development of therapeutics for oncology and behavioural brain disorders. The company develops orexin-1 antagonist for the treatment of binge eating disorder and anxiety; and atypical dopamine transporter inhibitor (DAT) to treat fatigue and narcolepsy. It also develops SFX-01 for the treatment of brain cancer glioblastoma and neurodevelopmental disorders.
Frequently asked questions
What is EVGEN PHARMA PLC LS-0025's market cap?
EVGEN PHARMA PLC LS-0025's market capitalization is EUR 5.29M.
What does EVGEN PHARMA PLC LS-0025 do?
Theracryf Plc, a clinical stage therapeutics company, engages in the development of therapeutics for oncology and behavioural brain disorders. The company develops orexin-1 antagonist for the treatment of binge eating disorder and anxiety;